Clinical Trial: Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia

U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298824) titled 'Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia' on Nov. 23.

Brief Summary: To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Myopia Progressing

Intervention: BIOLOGICAL: Investigational Bifidobacterium Preparation MR-61

Oral administration of the investigational probiotic powder MR-61. The primary component is Bifidobacterium. Dosage: one sachet, 2-3 times daily, for 3 months.

OTHER: Placebo for MR-61

Oral administration of a m...